Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting.

This article discusses the impact of 1q amplification, a chromosomal abnormality, on the outcomes of patients with multiple myeloma (MM) who were treated with daratumumab, carfilzomib, and dexamethasone (DKd) in a real-world clinical setting. The study analyzed data from 35 patients who received DKd treatment and found that patients with 1q amplification had significantly shorter progression-free survival (PFS) and overall survival (OS) compared to those with 1q gain or without 1q abnormalities. The study suggests that 1q amplification may be a poor prognostic factor in MM patients undergoing daratumumab-based treatment. However, the study has limitations due to its retrospective nature and small sample size. [Extracted from the article]